For patients with little LDL receptor function, LDL receptor-independent treatment targeting ANGPTL3 through monoclonal therapies are now available, or in the future, antisense/small interfering RNA-based approaches offer alternative approaches.
Editors
Editor-in-Chief Valentin Fuster, MD, PhD, MACC
CME EditorRagavendra R. Baliga, MD
Authors Julia Brandts, MD
Kausik K. Ray, BSC (HONS), MBCHB, MD, MPHIL (CANTAB)
Important Dates
Date of Release: October 25, 2021Term of Approval/Date of CME/MOC/ECME Expiration: October 24, 2022